Jan Van den Brande

2.1k citations

48 papers · 1.1k indexed · h-index 16

Oncology top 10%
- Cancer Treatment and Pharmacology 8
- Colorectal Cancer Treatments and Studies 6
- Cancer Immunotherapy and Biomarkers 5
- Neutropenia and Cancer Infections 4
Otorhinolaryngology top 10%
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 5
- Gastric Cancer Management and Outcomes 4
Pathology and Forensic Medicine top 10%
Hepatology top 10%
Surgery
- Bladder and Urothelial Cancer Treatments 5
- Urinary and Genital Oncology Studies 4

Co-authors: D. Schrijvers Sander van Deventer Daan W. Hommes Maikel P. Peppelenbosch Jan B. Vermorken Henri Braat A. Prové Filip De Vos
Cited by: Oncology Otorhinolaryngology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (2 papers)Gastroenterology (4 papers)American Journal of Clinical Nutrition (1 paper)
Partner nations: Belgium Netherlands France

In The Last Decade

Jan Van den Brande

45 papers receiving 1.0k citations

Peers

Countries citing papers authored by Jan Van den Brande

Since Specialization

Citations

This map shows the geographic impact of Jan Van den Brande's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Van den Brande with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Van den Brande more than expected).

Fields of papers citing papers by Jan Van den Brande

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Van den Brande. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Van den Brande. The network helps show where Jan Van den Brande may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jan Van den Brande, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jan Van den Brande Line = papers co-authored together Jan Van den Brande links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) BMC Cancer ·Nieves Martínez Chanzá,Louisa Soukane,Philippe Barthélémy,Aurélien Carnot,Thierry Gil,Vinciane Casert,Vincent Vanhaudenarde,Brieuc Sautois,L. Staudacher,Jan Van den Brande,Stéphane Culine,Emmanuel Seront,Marco Gizzi,Simone Albisinni,Thibault Tricard,J.-C. Fantoni,Marianne Paesmans,Rafael Caparica,Thierry Roumeguère,Ahmad Awada	2021	12
2	659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC) Annals of Oncology ·Nieves Martínez Chanzá,Aurélien Carnot,Philippe Barthélémy,Vinciane Casert,Brieuc Sautois,Jan Van den Brande,Vincent Vanhaudenarde,L. Staudacher,Emmanuel Seront,Stéphane Culine,Marco Gizzi,Thierry Gil,Marianne Paesmans,Nuria Kotecki,M. Ignatiadis,Simone Albisinni,J.-C. Fantoni,Thibault Tricard,Thierry Roumeguère,Ahmad Awada	2021	5
3	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer Current Treatment Options in Oncology ·Konstantinos Papadimitriou,Christian Rolfo,E. Dewaele,Mick van de Wiel,Jan Van den Brande,Sevilay Altıntaş,Manon Huizing,Pol Specenier,Marc Peeters	2015	9
4	Giant primary right ventricular synovial sarcoma: European Heart Journal ·Michael Wolf,Jan Van den Brande,Inez Rodrigus,Bernard P. Paelinck	2014	3
5	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study Investigational New Drugs ·Yohann Loriot,Karim Fizazi,Robert J. Jones,Jan Van den Brande,R. Molife,Aurelius Omlin,Nicholas D. James,Edwina Baskin-Bey,Marten Heeringa,Benoît Baron,Gertjan M. Holtkamp,Taoufik Ouatas,Johann S. de Bono	2014	54
6	Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors Cancer Chemotherapy and Pharmacology ·Emiliano Calvo,Jan B. Vermorken,Sandrine Hiret,Jordi Rodón,Javier Cortés,Hélène Senellart,Jan Van den Brande,J. Dyck,Aurélie Pétain,Pierre Ferré,Jaafar Bennouna	2012	3
7	Endoscopic Trimodal Imaging Detects Colonic Neoplasia as Well as Standard Video Endoscopy Gastroenterology ·Teaco Kuiper,Frank J.C. van den Broek,A.H.J. Naber,Ellert J. van Soest,Pieter Scholten,Rosalie C. Mallant–Hent,Jan Van den Brande,Jeroen M. Jansen,Arnoud H. A. M. van Oijen,Willem A. Marsman,Jacques Bergman,Paul Fockens,Evelien Dekker	2011	69
8	Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study Anti-Cancer Drugs ·Pol Specenier,Marika Rasschaert,Jan Van den Brande,J. Dyck,Dirk Schrijvers,Manon Huizing,Jan B. Vermorken	2010	1
9	Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck American Journal of Clinical Oncology ·Pol Specenier,Marika Rasschaert,Philippe Vroman,Jan Van den Brande,J. Dyck,Dirk Schrijvers,Manon Huizing,Jan B. Vermorken	2010	14
10	A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck BMC Cancer ·Pol Specenier,Joost Weyler,Carl Van Laer,Daniëlle Van den Weyngaert,Jan Van den Brande,Manon Huizing,Sevilay Altıntaş,Jan B. Vermorken	2009	8
11	A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours British Journal of Cancer ·Marika Rasschaert,D. Schrijvers,Jan Van den Brande,J. Dyck,Johan Bosmans,K Merkle,Jan B. Vermorken	2007	39
12	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Annals of Oncology ·C.-H. Köhne,Jacques De Grève,J. T. Hartmann,István Láng,Philippe Vergauwe,Karl‐Friedrich Becker,D. Braumann,E. Joosens,Lothar Müller,Jos Janssens,Carsten Bokemeyer,Peter Reimer,Hartmut Link,E. Späth‐Schwalbe,H. Wilke,Harry Bleiberg,Jan Van den Brande,Muriel Debois,Ullrich Bethe,Eric Van Cutsem	2007	127
13	A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors Anti-Cancer Drugs ·Marika Rasschaert,Dirk Schrijvers,Jan Van den Brande,J. Dyck,Johan Bosmans,K Merkle,Jan B. Vermorken	2007	30
14	Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection HIV Medicine ·Robert Colebunders,Emmanuel Bottieau,Jan Van den Brande,Cécile Colpaert,E. Van Marck	2004	12
15	Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function American Journal of Clinical Nutrition ·Henri Braat,Jan Van den Brande,Erik van Tol,Daan W. Hommes,Maikel P. Peppelenbosch,Sander van Deventer	2004	180
16	Pneumonectomy for Lung Metastases: Report of Ten Cases The Thoracic and Cardiovascular Surgeon ·Jeroen Hendriks,Bart Van de Putte,Sander Romijn,Jan Van den Brande,Jan B. Vermorken,Paul Van Schil	2003	3
17	Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer—significant effect of food intake on the bioavailability of the oral camptothecin analogue European Journal of Cancer ·Patrick Schöffski,Alexander Herr,J. B. Vermorken,Jan Van den Brande,J. H. Beijnen,Hilde Rosing,Joseph Volk,Arnold Ganser,Sabine Adank,H.J Botma,J. Wanders	2002	31
18	Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature British Journal of Cancer ·J. Pelgrims,Filip De Vos,Jan Van den Brande,D. Schrijvers,A. Prové,Jan B. Vermorken	2000	169
19	Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer Annals of Oncology ·Jan Van den Brande,D. Schrijvers,C Colpaert,Jan B. Vermorken	1999	11
20	Somatosensory Evoked Potentials in Term and Preterm Infants in Relation to Postconceptional Age and Birth Weight Neuropediatrics ·J. J. Bongers-Schokking,Eileen J. Colon,Richard A Hoogland,Jan Van den Brande,Christianne J.M. de Groot	1990	12

About Jan Van den Brande

Jan Van den Brande is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine, having authored 48 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers), Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Gastric Cancer Management and Outcomes (4 papers), Neutropenia and Cancer Infections (4 papers) and Urinary and Genital Oncology Studies (4 papers). The work is most often cited by research in Oncology (427 citations), Otorhinolaryngology (44 citations) and Pulmonary and Respiratory Medicine (293 citations). Jan Van den Brande has collaborated with scholars based in Belgium, Netherlands and France. Frequent co-authors include D. Schrijvers, Sander van Deventer, Daan W. Hommes, Maikel P. Peppelenbosch, Jan B. Vermorken, Henri Braat, A. Prové, Filip De Vos, Jan B. Vermorken and Joachim Sieper. Their work appears in journals such as Journal of Clinical Oncology, Gastroenterology and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact